Clinical Trial Search

Primary: Absolute Change From Baseline in Mean Lumbar Spine (L2 - L4) BMD — 0.7916; 0.7977; 0.7977; 0.8069 g/cm^2

Primary: Effective Dose 50% (ED50) — 141 ug

Primary: Change From Baseline to 8 Weeks in 24-Item Hamilton Depression Rating Scale (HAMD-24) Item 7 (Work and Activities) — -1.32; -1.07; -1.37; -0.93 units on a scale — p=0.051

Primary: Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours — 492.2; 326.3 Micrograms — p=0.05

Primary: Percentage of Participants Who Discontinued Zolpidem Therapy — 28.8; 32.7 Percentage of participants — p=0.484

Primary: Number of Participants With Complete Response — 0 participants

Primary: Change From Baseline to Week 4 in Blepharospasm Disability Index — -2.8; -1.3 Points on Scale

Primary: Mean Pruritus Severity Score Over the First Week of Treatment — 1.02; 1.18 Units on a scale — p=<0.001

Primary: Percentage Change in Partial Seizure Frequency (All Partial Seizure Types) Between Baseline and the 12 Week Observation Period — -33.33 percentage change in events

Primary: ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score — 40.7; 38.6; 32.3; 37.3 units on a scale — p=<0.001

Primary: Number of Participants With Immunological Response to Challenge Dose in Terms of Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration — 53; 21 participants

Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 2; 2; 3 Participants

Primary: Efficacy and Safety of Rotigotine Used During Surgery Under General Anaesthesia Assessed by Anaesthesiologist. — 5.0 Score on scale

Primary: Time-Normalized Area Under the Change From Pre-Dose Curve for Forced Expiratory Volume in One Second Measured Over 24 Hours — 0.156; 0.173 liters

Primary: Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment. — 86.0…